AZ Respiratory Head: Fasenra As Add-On Maintenance Can Reduce Exacerbations
Executive Summary
AstraZeneca's head of respiratory tells Scrip BORA Phase III data should reinforce and extend physician confidence in Fasenra as a long-term asthma biologic. The drug is also driving wider growth of biologics in asthma.
You may also be interested in...
All Over For AZ's Fasenra In COPD With Second Trial Fail
It is curtains for AstraZeneca's asthma therapy Fasenra as a COPD treatment after the failure of the TERRANOVA trial, which could be good news for GSK's fellow interleukin-5 drug Nucala, despite the latter's own mixed Phase III data.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.